YWHAB Antibody

What is YWHAB and what are its key functions in cellular processes?

YWHAB (14-3-3 beta/alpha) belongs to the 14-3-3 family of proteins responsible for signal transduction by binding to phosphoserine-containing proteins. It functions as an adapter protein involved in regulating both general and specialized signaling pathways. The protein interacts with RAF1 and CDC25 phosphatases, linking mitogenic signaling and cell cycle machinery .

YWHAB binds to numerous proteins through recognition of phosphoserine or phosphothreonine motifs, generally resulting in modulation of the binding partner's activity. It plays critical roles in:

• Cell cycle regulation

• Apoptosis

• Signal transduction

• Protein trafficking

• Regulation of PI3K/AKT signaling pathway

Research has demonstrated that YWHAB is expressed in both plants and mammals, with significant implications for cancer research, particularly in breast cancer and colon cancer models .

What detection methods are validated for YWHAB antibodies and at what dilutions?

YWHAB antibodies have been validated for multiple detection methods, with specific optimal dilutions depending on the application:

For optimal results, it is recommended to titrate the antibody in each specific testing system. Many antibodies require specific antigen retrieval methods, such as TE buffer pH 9.0 or citrate buffer pH 6.0 for IHC applications .

How should YWHAB antibodies be stored to maintain optimal activity?

Proper storage is crucial for maintaining antibody activity. Based on manufacturer recommendations:

• For short-term storage (up to 1 month): Store at 4°C

• For long-term storage: Store at -20°C

• Avoid repeated freeze-thaw cycles to prevent degradation

• Most YWHAB antibodies are supplied in stabilizing buffers such as:

  • PBS with 0.02% sodium azide and 50% glycerol, pH 7.3

  • Phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol

Under proper storage conditions, YWHAB antibodies typically maintain stability for approximately 12 months at -20°C .

How does YWHAB affect breast cancer cell behavior and what evidence supports its potential as a biomarker?

YWHAB has demonstrated significant effects on breast cancer cell behavior through multiple mechanisms. Recent studies provide compelling evidence for its role:

YWHAB knockdown experiments have shown:

• Inhibition of cell migration, proliferation, and epithelial-to-mesenchymal transition (EMT) in all subtypes of tumor cell lines

• Significant reduction in mesenchymal marker expression and upregulation of epithelial marker expression in aggressive miRNA overexpressed and triple-negative cell lines

As a potential biomarker:

• YWHAB expression is significantly higher in breast cancer biopsy tissue compared to control tissues

• YWHAB is expressed in all hormonal subtypes of breast cancer tumors

• Increased expression is observed in advanced tumor stages

• High expression is linked to poor patient survival (patients with high YWHAB expression showed 75% 5-year survival rate compared to 85% for those with low expression)

ROC curve analysis revealed:

• YWHAB alone shows a statistically significant AUC of 0.734 in tumor tissues, suggesting potential as a tumor marker

• YWHAB combined with pri-miR-526b shows promise as a blood biomarker (AUC of 0.711, p = 0.032)

These findings indicate YWHAB may serve as both a prognostic biomarker and therapeutic target in breast cancer, particularly when combined with other markers .

What methodologies are recommended for YWHAB knockdown experiments and what phenotypic changes should researchers expect?

For effective YWHAB knockdown experiments, the following methodologies have been validated:

Knockdown Protocol:

• siRNA transfection using lipofectamine methods at 1 nM concentration

• Validated siRNA sequences:

  • 5'-GGCTGAGCGATATGATGATAT-3'

  • 5'-TGCAGCCTACACACCCAATTC-3'

• Control: scrambled siRNA (5'-TTCTCCGAACGTGTCACGT-3')

• Expected knockdown efficiency: 80% reduction in YWHAB gene expression compared to scrambled control after 24 hours

Validation Methods:

• RT-qPCR for mRNA expression

• Western blot for protein expression

• In-cell immunoblotting

• Immunocytochemistry

Expected Phenotypic Changes:

• In breast cancer models:

  • Reduced cell migration and invasion

  • Decreased proliferation

  • Increased cell cycle arrest at G₀/G₁ phase

  • Enhanced apoptosis

  • Decreased expression of mesenchymal markers (e.g., vimentin)

• In colon cancer models:

  • Suppressed proliferation

  • Promoted cell cycle arrest at G₀/G₁ phase

  • Increased apoptosis

  • Decreased cyclin D1 and Bcl2 expression

  • Increased p21 and Bax expression

These results should be observed approximately 24 hours post-knockdown, and functional assays should be conducted within this timeframe for optimal results .

How can researchers effectively validate YWHAB antibody specificity for their experimental model?

Validating antibody specificity is crucial for reliable experimental results. For YWHAB antibodies, researchers should implement a multi-faceted validation approach:

Positive and Negative Controls:

• Positive tissue controls: Human colon cancer tissue, human kidney, and mouse intestine have been validated

• Positive cell line controls: HepG2 cells, MCF7, MDA-MB-231 cells

• Negative controls: Include secondary antibody alone, isotype controls

• Knockdown/knockout controls: Compare YWHAB antibody signal in wild-type vs. YWHAB knockdown samples

Cross-Reactivity Assessment:

• Test antibody against recombinant YWHAB protein

• Evaluate cross-reactivity with other 14-3-3 family members (especially important due to sequence homology)

• Check reactivity across species if working with non-human models

Multi-platform Validation:

• Compare results across different detection methods (WB, IHC, IF)

• Validate with at least two different antibodies targeting distinct epitopes

• For critical findings, confirm with antibody-independent methods (e.g., mass spectrometry)

Technical Validation:

• Perform antibody titration experiments to determine optimal concentration

• Include antigen competition assays

• For IHC/IF applications, test different fixation and antigen retrieval methods (e.g., TE buffer pH 9.0 vs. citrate buffer pH 6.0)

By implementing these validation steps, researchers can ensure high confidence in their YWHAB antibody specificity and experimental results.

What are the optimal protocols for immunohistochemical detection of YWHAB in different tissue types?

Standard IHC Protocol for YWHAB Detection:

• Tissue Preparation:

  • Formalin fixation and paraffin embedding is standard

  • Section thickness: 4-6 μm is optimal for most applications

• Antigen Retrieval:

  • Primary recommendation: TE buffer pH 9.0

  • Alternative method: Citrate buffer pH 6.0

  • Heat-induced epitope retrieval for 15-20 minutes

• Blocking and Antibody Application:

  • Block with 1% BSA in PBS for 1 hour at room temperature

  • Primary antibody dilution: 1:50 - 1:200 for most YWHAB antibodies

  • Incubation: Overnight at 4°C for optimal results

  • Secondary antibody: Appropriate HRP-conjugated or fluorescent secondary antibody (1:1000 - 1:5000)

• Detection Systems:

  • For brightfield microscopy: DAB substrate

  • For fluorescence: Compatible fluorophores with no spectral overlap if multiplexing

• Tissue-Specific Considerations:

  Tissue Type	Special Considerations	Expected Staining Pattern
  Breast cancer	Higher expression in tumor vs. normal tissue	Medium to high intensity cytoplasmic staining
  Colon cancer	Suggested as positive control	Strong cytoplasmic staining
  Kidney	Validated for normal control	Medium intensity staining
  Brain tissue	High endogenous expression	Primarily neuronal staining

• Quantification Methods:

  • H-score (multiplication of intensity score by percentage of positive cells)

  • Digital imaging analysis for objective quantification

  • Compare with validated controls for relative expression levels

How can researchers troubleshoot non-specific binding and false positives when using YWHAB antibodies?

When encountering non-specific binding or false positives with YWHAB antibodies, implement the following troubleshooting strategies:

Common Issues and Solutions:

• High Background Signal:

  • Increase blocking time (2 hours instead of 1 hour)

  • Use 3-5% BSA instead of 1% BSA

  • Add 0.1-0.3% Triton X-100 to reduce non-specific binding

  • Ensure adequate washing steps (minimum 3 x 5 minutes)

  • For tissue sections, consider using animal serum matching secondary antibody species

• Cross-Reactivity with Other 14-3-3 Family Members:

  • Select antibodies targeting unique epitopes of YWHAB (AA 217-246 or AA 56-85 regions show higher specificity)

  • Validate with YWHAB knockdown controls

  • Consider epitope-specific antibodies when possible

• False Positive Western Blot Bands:

  • YWHAB expected molecular weight: 28 kDa

  • Use gradient gels for better resolution

  • Include positive controls with known YWHAB expression

  • Consider longer blocking times or alternate blocking agents (milk vs. BSA)

  • Check for protein degradation in sample preparation

• Inconsistent IHC Results:

  • Test multiple antigen retrieval methods

  • Standardize fixation time and conditions

  • Optimize antibody concentration through titration

  • Include appropriate positive and negative tissue controls

  • Consider batch effects in processing and staining

• Verification Approaches:

  • Secondary antibody-only controls to assess non-specific binding

  • Pre-absorption with recombinant YWHAB protein

  • Parallel staining with two different YWHAB antibodies targeting distinct epitopes

  • Correlation of protein detection with mRNA expression data

What experimental design considerations are essential when studying YWHAB in cancer models?

When designing experiments to study YWHAB in cancer models, researchers should consider the following critical factors:

Experimental Design Framework:

• Model Selection:

  • Cell lines: Use multiple cell lines representing different cancer subtypes

    • For breast cancer: Include luminal A (MCF7), HER2-enriched (SKBR3), and triple-negative (Hs578T) cell lines

    • For colon cancer: Include cell lines with varying YWHAB expression

  • Animal models: Consider both xenograft and genetic models

  • Patient-derived samples: Include paired normal-tumor samples when possible

• Control Selection:

  • For cell lines: Use appropriate non-cancerous epithelial cells (e.g., HIEC-6 for intestinal studies)

  • For tissue studies: Use both adjacent normal tissue and true normal tissue from healthy donors

  • For RNA studies: Include housekeeping gene panels validated for the specific tissue type

• Intervention Design:

  • Knockdown studies: Use both transient (siRNA) and stable (shRNA) approaches

  • Overexpression studies: Use both constitutive and inducible systems

  • Include rescue experiments to confirm specificity

  • Consider timing of analyses (24h post-knockdown shows optimal results)

• Outcome Measurements:

  Functional Assay	Key Metrics	Expected YWHAB Effect
  Proliferation	Cell count, CCK-8 assay	Knockdown decreases proliferation
  Migration	Wound healing, transwell	YWHAB overexpression reduces migration
  Invasion	Matrigel invasion assay	YWHAB overexpression inhibits invasion
  Cell cycle	Flow cytometry	YWHAB knockdown arrests cells at G₀/G₁
  Apoptosis	TUNEL assay, Annexin V	YWHAB knockdown promotes apoptosis
  EMT	Epithelial/mesenchymal markers	YWHAB affects vimentin expression

• Translation to Clinical Relevance:

  • ROC curve analysis for biomarker potential (AUC ≥ 0.70 indicates effective marker)

  • Survival analysis: Kaplan-Meier plots correlating YWHAB expression with patient outcomes

  • Multi-marker approaches: Combine YWHAB with other markers (e.g., pri-miR-526b)

• Validation Approaches:

  • Utilize both in silico and in situ validation

  • Cross-platform validation (e.g., IHC, Western blot, and qPCR)

  • Independent cohort validation

  • Consider both mRNA and protein-level analyses

Following these experimental design principles will ensure robust and reproducible findings when studying YWHAB in cancer models.

How do microRNAs regulate YWHAB expression and function in breast cancer progression?

The relationship between microRNAs and YWHAB represents an important regulatory mechanism in breast cancer progression:

Key microRNA-YWHAB Interactions:

• miR-526b and miR-655 Overexpression Effects:

  • YWHAB was identified in the secretome of miR-526b and miR-655 overexpressed breast cancer cell lines

  • Both at mRNA and protein levels, suggesting regulatory interaction

  • These miRNAs possibly regulate YWHAB through indirect mechanisms

• Regulatory Mechanism:

  • In silico analysis identified transcription factors that negatively regulate YWHAB, including KLF10, MEIS2, NANOG, MYC, and FOXP1

  • These transcription factors may be targeted by the miRNAs

  • When miRNAs abrogate expression of these negative regulators, YWHAB expression increases in miRNA-overexpressed cells

• Functional Consequences:

  • YWHAB knockdown in miRNA-high expressing cell lines reverses miRNA-induced aggressive breast cancer phenotypes

  • Specifically affects epithelial-to-mesenchymal transition (EMT)

  • Suggests YWHAB is a key player in oncogenic miR-526b and miR-655-induced functions

• Combined Biomarker Potential:

  • pri-miR-526b alone is a sensitive blood biomarker for early breast cancer detection

  • When combined with YWHAB, the diagnostic potential improves

  • Combined AUC value of 0.711 (p = 0.032) shows promise as a blood-based detection method

• Clinical Implications:

  • The miRNA-YWHAB axis represents a potential therapeutic target

  • Targeting this axis could potentially reduce aggressive phenotypes in breast cancer

  • Requires further validation in larger clinical cohorts

These findings suggest that understanding the complex interplay between specific microRNAs and YWHAB could lead to new diagnostic and therapeutic approaches in breast cancer management.

What signaling pathways are affected by YWHAB modulation and how might this inform therapeutic strategies?

YWHAB modulation affects multiple signaling pathways with significant implications for therapeutic development:

Key Signaling Pathways Affected:

• PI3K/AKT Pathway:

  • YWHAB interacts with PI3K regulatory subunit 2 (PIK3R2)

  • This interaction affects downstream PI3K/AKT signaling

  • Potential binding was predicted by the Monarch Initiative database and confirmed by co-immunoprecipitation

  • Therapeutic relevance: PI3K inhibitors may be particularly effective in YWHAB-overexpressing tumors

• Cell Cycle Regulation:

  • YWHAB knockdown affects expression of:

    • Cyclin D1 (decreased) - G1-S cell-cycle transition regulator

    • p21 (increased) - G1-checkpoint CDK inhibitor

  • Results in G0/G1 phase arrest

  • Therapeutic relevance: Combination with CDK inhibitors might enhance cell cycle arrest

• Apoptosis Pathway:

  • YWHAB modulation affects:

    • Bcl2 (anti-apoptotic) - decreased with YWHAB knockdown

    • Bax (pro-apoptotic) - increased with YWHAB knockdown

  • Therapeutic relevance: Bcl2 inhibitors could synergize with YWHAB targeting

• TNF Signaling Pathway:

  • Transcriptomics analysis of YWHAB overexpression identified differential expression of genes in the TNF signaling pathway (KEGG: map04688)

  • Therapeutic relevance: TNF pathway modulators could be explored in combination therapy

• EMT Regulation:

  • YWHAB overexpression downregulates vimentin (mesenchymal marker)

  • Weakens mesenchymal properties of cancer cells

  • Therapeutic relevance: Could reduce metastatic potential when targeted appropriately

Therapeutic Strategy Framework:

These pathway interactions highlight YWHAB as a potential therapeutic target in cancer, with particular promise for combination treatment strategies targeting multiple pathways simultaneously.

How do YWHAB expression patterns vary across cancer types and what are the implications for cancer diagnosis?

YWHAB expression patterns show significant variation across cancer types, with important diagnostic implications:

Cancer Type-Specific Expression Patterns:

• Breast Cancer:

  • Significantly higher expression in breast cancer biopsy tissue compared to control tissues

  • Expressed in all hormonal subtypes (luminal A, luminal B, HER2-enriched, triple-negative)

  • High expression linked to poor patient survival (75% vs. 85% 5-year survival)

  • Diagnostic value: AUC of 0.734 as tumor marker (p = 0.0012)

  • Blood biomarker potential: Limited alone, but improved when combined with pri-miR-526b (AUC of 0.711)

• Colon Cancer:

  • Upregulated in colon cancer cells compared to normal intestinal epithelial cells

  • Knockdown suppresses proliferation and promotes apoptosis

  • Serves as a validated positive control for IHC applications

  • Shows strong cytoplasmic staining pattern

• Cross-Cancer Expression Analysis:

  • Based on Human Protein Atlas data:

    • Normal tissues: Low to medium YWHAB staining

    • Cancer tissues: Medium (72.22%) to high (25%) intensity staining

  • TCGA PanCancer Atlas data shows higher YWHAB mRNA expression in tumor samples compared to normal tissues

Diagnostic Implications:

• Tissue-Based Diagnostics:

  • YWHAB shows promise as a tissue-based diagnostic marker

  • Particularly valuable in breast cancer tissue samples (AUC 0.734)

  • Can be assessed through standard IHC techniques using optimized protocols

• Liquid Biopsy Applications:

  • YWHAB alone has limited value as a blood biomarker (AUC 0.582, not significant)

  • Combined approaches show more promise:

    • YWHAB + pri-miR-526b: AUC 0.711 (p = 0.032)

  • Requires further validation in larger sample sets

• Prognostic Value:

  • High YWHAB expression correlates with poorer survival outcomes

  • 5-year survival rate differences:

    • High YWHAB: 75% survival

    • Low YWHAB: 85% survival

  • Suggests value as a prognostic biomarker

• Multi-Cancer Screening Potential:

  • Expression across multiple cancer types suggests potential for inclusion in pan-cancer screening panels

  • Different staining patterns and intensities can help differentiate cancer types

  • May be most valuable when combined with other cancer-specific markers

Understanding these cancer-specific expression patterns can guide the development of YWHAB-based diagnostic approaches, particularly in combination with other established or emerging biomarkers.

What are the most promising directions for YWHAB research in cancer biology and precision medicine?

Based on current findings, several promising research directions emerge for YWHAB in cancer biology and precision medicine:

• YWHAB as a Therapeutic Target:

  • Development of small molecule inhibitors specifically targeting YWHAB interactions

  • Investigation of YWHAB in combination therapy approaches, particularly with:

    • PI3K/AKT pathway inhibitors

    • Cell cycle regulators

    • Anti-metastatic agents

  • Exploration of YWHAB modulation to reverse EMT in metastatic cancer

• Multimodal Biomarker Approaches:

  • Further validation of YWHAB + pri-miR-526b as a blood biomarker in larger cohorts

  • Development of multiplexed detection methods for YWHAB and associated markers

  • Investigation of YWHAB in liquid biopsy applications beyond blood (e.g., exosomes)

• Mechanistic Understanding:

  • Detailed characterization of YWHAB interactions with transcription factors KLF10, MEIS2, NANOG, MYC, and FOXP1

  • Further exploration of the relationship between miRNAs and YWHAB expression

  • Investigation of post-translational modifications of YWHAB and their functional consequences

• Cancer Subtype Specificity:

  • Comprehensive analysis of YWHAB function across cancer subtypes

  • Determination of cancer-specific interactomes

  • Identification of subtype-specific vulnerabilities related to YWHAB expression

• Clinical Translation:

  • Development and validation of standardized YWHAB detection methods for clinical use

  • Prospective studies correlating YWHAB expression with treatment response

  • Investigation of YWHAB as a predictive marker for specific therapies

These research directions have the potential to significantly advance our understanding of YWHAB's role in cancer biology and to translate these findings into clinically relevant applications in precision medicine.

What methodological advances are needed to better study YWHAB function in complex biological systems?

Several methodological advances would enhance our ability to study YWHAB function in complex biological systems:

• Advanced Protein Interaction Analysis:

  • Development of proximity labeling techniques specific for YWHAB interactions

  • Application of CRISPR-based screening to identify synthetic lethal interactions

  • Implementation of advanced mass spectrometry approaches to characterize YWHAB interactome in different cellular contexts

  • Improved co-immunoprecipitation protocols with higher specificity for transient interactions

• Improved In Vivo Modeling:

  • Generation of conditional YWHAB knockout mouse models

  • Development of patient-derived xenografts (PDXs) with modulated YWHAB expression

  • Implementation of organoid models to study YWHAB in 3D microenvironments

  • Application of in vivo imaging techniques to track YWHAB function in real-time

• Single-Cell Analysis:

  • Integration of single-cell proteomics and transcriptomics to understand YWHAB heterogeneity

  • Spatial transcriptomics to map YWHAB expression in tumor microenvironments

  • Development of YWHAB-specific probes for live-cell imaging

  • Single-cell pathway analysis to understand contextual functions

• Quantitative Assay Development:

  • Standardized protocols for absolute quantification of YWHAB protein levels

  • Development of high-throughput functional assays for YWHAB activity

  • Improved methods for detecting post-translational modifications of YWHAB

  • Better techniques for distinguishing between YWHAB isoforms and family members

• Computational Approaches:

  • Machine learning algorithms to predict YWHAB binding partners based on phosphoproteomics data

  • Network analysis tools to position YWHAB within cellular signaling networks

  • Structural biology approaches to design specific YWHAB modulators

  • Systems biology frameworks to integrate multi-omics data related to YWHAB function